Through Sapient’s services for dynamic biomarker discovery, your studies can leverage cutting-edge technology to rapidly map non-genetic factors that contribute to disease – a largely untapped area for discovery from which up to 80% of disease risk originates.
Build a more complete understanding of disease risk, progression, and prognosis.
Our data science team provides expertise to integrate and interpret generated data.
Confirm how your identified biomarkers behave across 100,000+ biosamples, with representation of a range of diseases.
Disease processes are complex and dynamic. Individuals with the same genetic disorder or diagnosis can have varied prognosis and response to treatment, as their underlying disease may be influenced by a range of internal and external exposures experienced over time.
Sapient enables you to explore these factors through discovery of dynamic biomarkers that can be used to subtype disease and stratify patients.
The next insights for disease research lie beyond the genome, as up to 80% of disease risk is attributable to non-genetic factors.
We focus on the biomarkers that read out these non-genetic influences, using next-generation mass spectrometry systems to capture >15,000 small molecule biomarker per sample (cellular, preclinical, and human), including those that have yet to be characterized.
Our nontargeted approach leads us to the most biologically relevant biomarkers, which we can cross-validate in our Human Biology Database.
Proteins hold information that is critical to decipher the functional mechanisms underlying disease. We enable you to rapidly layer protein biomarkers into your research using our high-specificity methods.
Our discovery proteomics offering provides direct measure of thousands of proteins per sample, with coverage and throughput that is scalable to your study need. We can also run targeted assays for difficult-to-measure proteins.
Our data science team works alongside investigators to provide their biocomputational expertise in analyzing large-scale, multi-omics datasets.
They help to interpret the data we generate to identify biologically significant biomarkers related to your disease. They can also cross-validate key biomarkers by mining our Human Biology Database with data from 100,000+ biosamples, to evaluate how the biomarker behaves in independent patient groups.
If there are difficult-to-measure metabolite, lipid, or protein biomarkers you are interested in exploring, we can help define the ideal profiling approach based on your samples and study objectives.
We also offer a CLIA-certified, CAP-accredited clinical laboratory to support the development of CLIA assays.
Connect with our scientists to discuss your study to the biological questions you want to answer. We’re here to help you apply robust, creative omics approaches at any phase of development.